Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 28, 2021

View Archived Issues

Selective functional impairment of HIV-specific CD8+ T cells heralds aborted HIV control

U.S. Department of Health & Human Services patents T-cell receptors against mutated RAS

New HDAC6 inhibitors identified at Chong Kun Dang Pharmaceutical

Hanyang University discovers MAPK10 inhibitors

New PDE4 inhibitors divulged by Suzhou Longbiotech Pharmaceuticals

TIMP-1 and CKM as biomarkers of therapeutic response for exon-skipping therapies in DMD

Ninjurin-1-associated eRNA linked to glioblastoma multiforme

Association between heterozygous variant in GRM1 gene and autosomal dominant cerebellar ataxia

New proteasome inhibitors show antimalarial promise

RNA therapeutic MC-30 shows efficacy in rodent models of HNSCC

Beam Therapeutics presents in vitro data on use of cytosine base editors for hepatitis B

NINDS grant supports Sinopia's IND-enabling studies of Parkinson's candidate

Targeting nigral SRY synthesis may be therapeutic for men with Parkinson's disease

Dare Bioscience awarded NICHD grant for DARE-LARC1 user-controlled contraceptive

Oblique reports in vivo data on aG13D monoclonal antibodies for colorectal cancer

Serotonin inhibition reduces tumor growth and increases CD8+ T-cell infiltration in tumor models

Diaprost licenses theranostic antibody hu5A10 to Radiopharm

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...